Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Geusens

Showing results (41-50 of 147) with videos related to

Pageof 15
Sort By:
Acta Clinica Belgica|April 23, 2017
Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE studyPatrick Durez, Marie Vanthuyne, Muhammad S Soyfoo, et al.
Calcified Tissue International|March 12, 2020
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical TrialPiet Geusens, David L Kendler, Astrid Fahrleitner-Pammer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 3, 2004
Musculoskeletal rehabilitation in osteoporosis: a reviewMichael Pfeifer, Mehrsheed Sinaki, Piet Geusens, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 27, 2005
Risk of new clinical fractures within 2 years following a fractureSvenhjalmar van Helden, Jochen Cals, Fons Kessels, et al.
Arthritis Research & Therapy|May 19, 2005
Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritisLoes Linsen, Marielle Thewissen, Kurt Baeten, et al.
Arthritis Research & Therapy|June 9, 2016
The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritisLiesbeth M De Winter, Piet Geusens, Jan Lenaerts, et al.
Best Practice & Research. Clinical Rheumatology|September 25, 2019
Fracture liaison programsPiet Geusens, Sandrine P G Bours, Caroline E Wyers, et al.
Current Opinion in Rheumatology|May 18, 2013
NSAIDs and fracture healingPiet Geusens, Pieter J Emans, Joost J A de Jong, et al.
RMD Open|November 12, 2015
OsteoRheumatology: a new discipline?Marta Favero, Andrea Giusti, Piet Geusens, et al.
Arthritis and Rheumatism|March 31, 2006
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialRene Westhovens, David Yocum, John Han, et al.
Pageof 15

Showing results (41-50 of 147) with videos related to

Sort By:
Pageof 15
Acta Clinica Belgica|April 23, 2017
Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE studyPatrick Durez, Marie Vanthuyne, Muhammad S Soyfoo, et al.
Calcified Tissue International|March 12, 2020
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical TrialPiet Geusens, David L Kendler, Astrid Fahrleitner-Pammer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 3, 2004
Musculoskeletal rehabilitation in osteoporosis: a reviewMichael Pfeifer, Mehrsheed Sinaki, Piet Geusens, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 27, 2005
Risk of new clinical fractures within 2 years following a fractureSvenhjalmar van Helden, Jochen Cals, Fons Kessels, et al.
Arthritis Research & Therapy|May 19, 2005
Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritisLoes Linsen, Marielle Thewissen, Kurt Baeten, et al.
Arthritis Research & Therapy|June 9, 2016
The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritisLiesbeth M De Winter, Piet Geusens, Jan Lenaerts, et al.
Best Practice & Research. Clinical Rheumatology|September 25, 2019
Fracture liaison programsPiet Geusens, Sandrine P G Bours, Caroline E Wyers, et al.
Current Opinion in Rheumatology|May 18, 2013
NSAIDs and fracture healingPiet Geusens, Pieter J Emans, Joost J A de Jong, et al.
RMD Open|November 12, 2015
OsteoRheumatology: a new discipline?Marta Favero, Andrea Giusti, Piet Geusens, et al.
Arthritis and Rheumatism|March 31, 2006
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialRene Westhovens, David Yocum, John Han, et al.
Pageof 15